ClinicalTrials.gg
CompletedNCT03781063Updated Jan 28, 2026

Evaluation of Lasofoxifene Versus Fulvestrant in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

A Phase 2 interventional study of Lasofoxifene and Fulvestrant in Locally Advanced or Metastatic Breast Cancer, sponsored by Sermonix Pharmaceuticals Inc.. Completed at 51 sites in 3 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by Sermonix Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This is an open label, randomized, multicenter study evaluating the activity of lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic ER+/HER2- breast cancer with an acquired ESR1 mutation and who have disease progression on an aromatase inhibitor (AI) in combination with a cyclin dependent kinase (CDK) 4/6 inhibitor.

The primary objective is to evaluate the progression free survival (PFS) of 5 mg lasofoxifene relative to fulvestrant for the treatment of pre- and postmenopausal women with locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation.

The secondary objectives are to evaluate:

  1. Clinical benefit rate (CBR) and Objective Response Rate (ORR)
  2. Duration of response
  3. Time to response
  4. Overall Survival (OS)
  5. Pharmacokinetics of lasofoxifene
  6. Quality of life (QoL): Quality of Life (QoL): vaginal assessment scale (VAS) and vulvar assessment scale (VuAS) questionnaires
  7. Safety of lasofoxifene
  8. Response to various ESR1 mutation (Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N).
Read the detailed description

Lasofoxifene is a potent SERM that has demonstrated in non-clinical models to prevent and treat breast cancer. In a large clinical osteoporosis trial, lasofoxifene reduced the incidence of ER+ breast cancer, which most likely represents a beneficial effect on clinically undetectable breast cancer. The clinical and non-clinical results are not unexpected based on the results seen with tamoxifen and fulvestrant as the mechanisms of action are similar. Moreover, the safety profile of lasofoxifene is well established in postmenopausal women and therefore a clinical trial investigating lasofoxifene for the treatment of breast cancer is scientifically justifiable.

Subjects with ESR1 mutations have endocrine resistance and shorter time to progression when treated with currently approved endocrine therapy. There is an unmet medical need for endocrine agents that can provide greater efficacy in this population. Non-clinical in vitro and in vivo studies with lasofoxifene have demonstrated efficacy. If this benefit translates to subjects with ESR1 mutated breast cancer cells, an important treatment option beyond fulvestrant will be available. The population being recruited in this trial are subjects with advanced breast cancer who have been treated with an AI in combination with a cyclin-dependent kinase (CDK) 4/6 inhibitor and who have an ESR1 mutation. The efficacy of endocrine agents in this population has never been prospectively studied. For this reason, this study will evaluate lasofoxifene in a randomized Phase 2 trial against a comparator to better evaluate the magnitude of the effect as well as to provide data to estimate the Phase 3 sample size.

In both non-clinical and clinical studies, fulvestrant has shown activity in ESR1 mutated breast cancer cells and will be used as the comparator in this Phase 2 study to better determine the relative clinical efficacy of lasofoxifene. The FDA approved fulvestrant dose will be used.

A major limiting factor in the administration of fulvestrant is its poor solubility requiring IM injection. The volume of administration limits the dose that can be administered. Initial clinical trials administered 250 mg of fulvestrant in 5 cc of castor oil as a single injection once monthly. Because the IM injections were well tolerated, loading and higher doses were investigated. This was found to have acceptable tolerability and resulted in greater efficacy. Limited by the volume of administration higher doses of fulvestrant cannot be investigated further.

Once the subject has consented to participate in the study, screening tests will be performed within 30 days of enrollment.

All subjects meeting the eligibility criteria will be first stratified into those with visceral metastasis and those without visceral metastasis. Each of these stratified groups will then be further stratified into those with the Y537S ESR1 mutation and those without this particular mutation. Each of the stratified groups will then be randomized 1:1 to receive either 5 mg/d of oral lasofoxifene or fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29, then every 4 weeks thereafter. Treatment will continue until radiographic or clinical evidence of disease progression. Enrolled subjects will be seen every 2 weeks for the first month of treatment and then monthly until progression. Efficacy assessments will be done every 8 weeks.

For subjects randomized to lasofoxifene, blood samples will be drawn to assess the population PK. Serum samples will be collected at each visit starting at Visit 0 (Day 1) through Final/ET visit to measure serum lasofoxifene concentration at time points outlined below. Serum samples for PK analysis will be collected before the time that the next lasofoxifene dose is ingested. The actual time and date of dosing on the previous day as well as dosing on the visit day, and the PK blood sampling time/date must be recorded for all subjects. Pharmacokinetic samples are to be collected before clinical lab blood sampling.

A maximum of 100 subjects will be randomized and it is expected that all subjects enrolled in the study will be treated until documented disease progression. It is estimated that full recruitment into the study will occur within 12 to 18 months with another 12 months of follow up before the primary outcome measure is analyzed.

02

Conditions studied

  • Locally Advanced or Metastatic Breast Cancer

Browse trials for

Keywords

  • Locally Advanced Breast Cancer
  • Metastatic Breast Cancer
  • Lasofoxifene
  • Fulvestrant
  • ER+/HER2
  • ESR1 mutation
03

In context

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

This study's enrollment of 100 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Sermonix Pharmaceuticals Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pre- or .

    Postmenopausal women are defined as:

    1. ≥60 years of age with no vaginal bleeding over the prior year, or
    2. \<60 years with "premature menopause" or "premature ovarian failure" manifest itself with secondary amenorrhea for at least 1 year and follicle stimulating hormone (FSH) and estradiol levels in the postmenopausal range according to institutional standards, or
    3. surgical menopause with bilateral oophorectomy. Note: premenopausal women who meet all of the other entry criteria must be maintained on ovarian suppression (such as Lupron) during the study and subjects counseled to use appropriate to prevent pregnancy.
  2. If possible, a of breast cancer tissue will be obtained to provide histological or cytological confirmation of ER+ and - disease as assessed by a local laboratory, according to the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines, using slides, paraffin blocks, or paraffin samples. If a biopsy is not possible, the ER and HER2 status from the tissue obtained at the time of the original diagnosis must confirm that the subject's cancer is ER+ and HER2-.
  3. Locally advanced or metastatic breast cancer with radiological or clinical evidence of progression on an AI in combination with a CDK 4/6 inhibitor for advanced breast cancer with demonstrated prior sensitivity to endocrine therapy (recurrence or progression after at least 12 months of treatment in the metastatic setting).
  4. Locally advanced or metastatic breast cancer with either measurable (according to 1.1) or non-.
  5. At least one or more of the following point ESR1 mutations as assessed in cell-free circulating tumor DNA (ctDNA) obtained from a blood (plasma) or tissue sample: Y537S, Y537C, D538G, E380Q, S463P, V534E, P535H, L536H, L536P, L536R, L536Q, or Y537N. The ctDNA sample collection must be obtained within 30 days prior to randomization to determine eligibility and baseline. Note: a prior genomic test confirming that the subject has an ESR1 mutation can be used to determine eligibility; however, an ESR1 sample must also be collected within 30 days of randomization.
  6. Subjects who have not received cytotoxic chemotherapy or those who have received one cytotoxic chemotherapy regimen in the or adjuvant setting prior to entry into the trial and/or no more than one chemotherapy regimen for metastatic breast cancer. Subjects must be free of all chemotherapy acute toxicity excluding alopecia and Grade II peripheral neuropathy before study entry.
  7. performance score of 0 or 1.
  8. Adequate organ function as shown by:

    1. (ANC) >/=1,500 cells/mm3
    2. count ≤100,000 cells/mm3
    3. >/=9.0 g/dl
    4. and AST levels ≤2.5 (ULN) or ≤5 in the presence of visceral metastasis
    5. total serum ≤1.5 X ULN (≤ 3 X ULN for subjects known to have Gilbert Syndrome)
    6. alkaline phosphatase level ≤ 2.5 X ULN
    7. of 40 ml/min or greater as calculated by the Cockcroft-Gault formula
    8. (INR), activated partial thromboplastin (aPTT), or partial thromboplastin time (PTT) \<2.0 X ULN.
  9. Able to swallow tablets.
  10. Able to understand and voluntarily sign a written before any screening procedures.

Exclusion criteria

Exclusion Criteria:

  1. Prior use of everolimus or other mammalian target of rapamycin (mTOR) inhibitor or phosphoinositide 3-kinase inhibitor (PI3K) inhibitors is excluded unless discontinued to reasons other than disease progression.
  2. Presence of .
  3. Lymphangitic carcinomatosis involving the lung.
  4. Impending visceral crisis in need of cytotoxic chemotherapy as assessed by the investigator.
  5. Radiotherapy within 30 days prior to randomization except in case of localized radiotherapy for analgesic purposes or for lytic lesions at risk of fracture, which can then be completed within 7 days prior to randomization. Subjects must have recovered from radiotherapy toxicities prior to randomization.
  6. History of long QTC syndrome or a QTC of >480 ms.
  7. History of a pulmonary embolus (PE) or deep vein thrombosis (DVT) within the last 6 months or any known thrombophilia. Subjects stable on anti-coagulants for maintenance are eligible as long as the DVT and/or PE occurred >6 months prior to enrollment and there is no evidence for active thrombosis. The use of low dose ASA is permitted.
  8. Any significant co-morbidity that would impact the study or the subject's safety.
  9. History of a positive (HIV), virus (HBV) or virus (HCV) at Screening. Subjects cured of hepatitis C (no viral load) are eligible.
  10. History of within the past 5 years (excluding breast cancer), except basal cell or squamous cell carcinoma of the skin curatively treated by surgery, or early stage cervical cancer.
  11. History of vaginal bleeding over the last year unless it is documented that the bleeding was due to non-uterine causes (e.g. vaginal atrophy).
  12. Uncontrolled hypertension defined as sitting systolic pressure >160 mm Hg or diastolic pressure >100 mm Hg at Screening.
  13. History of non-compliance to medical regimens.
  14. Unwilling or unable to comply with the protocol.
  15. Current participation in any clinical research trial involving an drug or device within the last 30 days.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Lasofoxifene

    5 mg/d of oral lasofoxifene

    Drug: Lasofoxifene

  • Active comparator
    Fulvestrant

    500 mg fulvestrant intramuscular (IM)

    Drug: Fulvestrant

Interventions

  • Estrogen receptor antagonist antineoplastic agent

  • Estrogen receptor antagonist antineoplastic agent

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS is defined as the interval from the date of randomization to the earlier date of first documented radiographic progression or death due to any cause

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of all subjects with a complete or partial response; or stable disease for \>/=24 weeks.

    Time frame: through study completion, an average of 1 year

  2. Objective Response Rate (ORR)

    ORR is defined as the percentage of subjects with either a complete response (CR) or a partial response (PR) as assessed by the RECIST 1.1 criteria.

    Time frame: through study completion, an average of 1 year

  3. Overall Survival (OS)

    OS is defined as time from randomization to death due to any cause.

    Time frame: through study completion, an average of 1 year

  4. Incidence of Adverse Events (AEs) and Serious AEs

    The type, severity (graded by Common Terminology Criteria for Adverse Events \[CTCAE version 5.0\]), course, duration, seriousness, and relationship to study treatment will be assess at each visit

    Time frame: through study completion, an average of 1 year

07

Study locations

51 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Yuma Regional Medical Center (JIT)
    Yuma, Arizona 85364, United States
  • City of Hope Comprehensive Cancer
    Duarte, California 91010, United States
  • Compassionate Care Research Group
    Fountain Valley, California 92708, United States
  • UCSF Cancer Center
    San Francisco, California 94115, United States
  • Rocky Mountain Cancer Centers
    Longmont, Colorado 80501, United States
  • Mayo Clinic Florida
    Jacksonville, Florida 32224, United States
  • Miami Cancer Institute
    Miami, Florida 33176, United States
  • Ocala Oncology Center (JIT)
    Oscala, Florida 34474, United States
  • Florida Cancer Specialists
    Tallahassee, Florida 32308, United States
  • The Bond Clinic Cancer & Research Center.
    Winter Haven, Florida 33880, United States
  • Emory University
    Atlanta, Georgia 30322, United States
  • Hawaii Cancer Care (JIT)
    Honolulu, Hawaii 96813, United States
  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University
    Chicago, Illinois 60611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Illinois Cancer Care (JIT)
    Peoria, Illinois 61615, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Beacon Health (JIT)
    South Bend, Indiana 46601, United States
  • University of Louisville / James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • FMH James M Stockman Cancer Institute (JIT)
    Frederick, Maryland 21702, United States
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
  • Hattiesburg Clinic Hematology/Oncology
    Hattiesburg, Mississippi 39401, United States
  • Saint Luke's Cancer Institute
    Kansas City, Missouri 64111, United States
  • HCA Midwest Health
    Kansas City, Missouri 64132, United States
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
  • Comprehensive Cancer Centers of Nevada (JIT)
    Las Vegas, Nevada 89128, United States
  • New Jersey Cancer Care and Blood Disorders (JIT)
    Belleville, New Jersey 07203, United States
  • Summit Medical Group (JIT)
    Florham Park, New Jersey 07932, United States
  • Roswell Park Comprehensive Cancer Center
    Buffalo, New York 14263, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • TriHealth Cancer Institute
    Cincinnati, Ohio 45220, United States
  • The Ohio State University - Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Ohio Health (JIT)
    Columbus, Ohio 43221, United States
  • UPMC Hillman Cancer Center
    Pittsburgh, Pennsylvania 15232, United States
  • Sanford Cancer Center (JIT)
    Sioux Falls, South Dakota 57104, United States
  • Tennessee Oncology Chattanooga
    Chattanooga, Tennessee 37404, United States
  • West Cancer Center
    Germantown, Tennessee 38138, United States
  • Tennessee Oncology/SCRI
    Nashville, Tennessee 37203, United States
  • Mary Crowley Cancer Research (JIT)
    Dallas, Texas 75230, United States
  • Oncology Consultants (JIT)
    Houston, Texas 77024, United States
  • Utah Cancer Specialists (JIT)
    Salt Lake City, Utah 84102, United States
  • Peninsula Cancer Institute
    Newport News, Virginia 23601, United States
  • The Ottawa Hospital
    Ottawa, Ontario K1H8L6, Canada
  • Sunnybrook Health Sciences Center
    Toronto, Ontario M4N3M5, Canada
  • CIUSSS de Saguenay-Lac-Saint Jean
    Chicoutimi, Quebec G7H5H6, Canada
  • Jewish General Hospital
    Montreal, Quebec H3T1E2, Canada
  • McGill University Health Centre
    Montreal, Quebec H4A3J1, Canada
  • Soroka University Medical Center
    Beersheba, Israel 84101, Israel
  • Hadassah Ein Kerem Medical Center
    Jerusalem, Israel 9112001, Israel
  • Rabin Medical Center
    Petah Tikva, Israel 49100, Israel
  • Sheba Medical Center
    Ramat Gan, Israel 52656021, Israel
08

References and documents

Publications

  • Goetz MP, Bagegni NA, Batist G, Brufsky A, Cristofanilli MA, Damodaran S, Daniel BR, Fleming GF, Gradishar WJ, Graff SL, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard TJ, Rugo HS, Sammons SL, Schwartzberg LS, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Gal-Yam EN. Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Ann Oncol. 2023 Dec;34(12):1141-1151. doi: 10.1016/j.annonc.2023.09.3104. PubMed 38072514 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2019 to primary completion in May 2025, 67 months.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 67 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2018
First posted
Dec 19, 2018
StartActual
Sep 20, 2019
Primary completionActual
May 8, 2025
CompletionActual
May 8, 2025
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03781063
Lead sponsor
Sermonix Pharmaceuticals Inc.
Collaborators
Linical Accelovance Group
Responsible party
Sponsor
First posted
Dec 19, 2018
Start date
Sep 20, 2019
Primary completion
May 8, 2025
Completion
May 8, 2025
Last update
Jan 28, 2026

Study contacts

Paul V. Plourde, MD
study director · Sermonix Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lasofoxifene

Start the discussion